Q-omics provides the consensus-scored IER5L profile across patient tissues and cancer cell-line models. IER5L expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, IER5L is differentially expressed in 15, with the highest sampling consensus in THCA. Additionally, IER5L RNA expression shows 14,804 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUAD, THCA, and TGCT as cancer lineages where IER5L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IER5L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IER5L survival associations across molecular data types. IER5L RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IER5L RNA expression–survival associations across cancer types. High IER5L expression shows unfavorable associations in LUAD, UVM, KIRP, LUSC, LGG and LIHC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for IER5L RNA expression.
This table summarizes IER5L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for IER5L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IER5L shows higher tumor expression in THCA, COAD, BLCA, HNSC, STAD and LUAD. The THCA box plot shows higher IER5L RNA expression in tumor versus normal tissue (log2 FC = +2.689, t-test p < 0.001).
This table shows molecular features associated with IER5L in patient tissues and cancer cell lines. In patient samples, IER5L shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, IER5L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and SOFT_TISSUE.
